The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of sunitinib (SU) in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (NET).
Takuji Okusaka
No relevant relationships to disclose
Tetsuhide Ito
No relevant relationships to disclose
Toshirou Nishida
No relevant relationships to disclose
Hisato Igarashi
No relevant relationships to disclose
Nobumasa Mizuno
No relevant relationships to disclose
Kazuo Hara
No relevant relationships to disclose
Chigusa Morizane
No relevant relationships to disclose
Shunsuke Kondo
No relevant relationships to disclose
Satoshi Hashigaki
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Nobuyuki Kimura
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Kyoko Okano
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Junichi Tanuma
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Mami Murakami
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Akira Sawaki
No relevant relationships to disclose
Kenji Yamao
No relevant relationships to disclose
Masayuki Imamura
No relevant relationships to disclose